New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
10:11 EDTICPTIntercept to present on POISE trial at EASL meeting
Intercept Pharmaceuticals announced presentations of key data at the International Liver Congress 2014, the 49th Annual Meeting of the European Association for the Study of the Liver, or EASL, being held in London from April 9-13.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
05:44 EDTICPTIntercept FLINT trial data shows OCA treatment increases fibrosis resolution
Subscribe for More Information
April 22, 2015
07:07 EDTICPTEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
April 17, 2015
10:00 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:53 EDTICPTIntercept initiated with a Buy, $465 target at UBS
UBS analyst Matthew Roden started shares of Intercept Pharmaceuticals with a Buy rating and $465 price target. Roden sees a favorable risk/reward ahead of the approval and commercial launch of the company's obeticholic acid, known as OCA, in primary biliary cirrhosis. Roden also thinks OCA's opportunity in nonalcoholic steatohepatitis is being undervalued at current share levels. Shares of Intercept closed yesterday up $2.53 to $274.44.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use